A Hawaiian woman, 37, was diagnosed with a rare instance of three overlapping neurological conditions caused by the body's ...

Explore the growing U.S. Zilbrysq (Zilucoplan) market, projected to expand at a CAGR of 21.64% post-FDA approval for anti-AChR antibody-positive generalized myasthenia gravis (gMG). The subcutaneous ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

Results from the Phase III PREVAIL trial (NCT05556096) of gefurulimab demonstrated a statistically significant and clinically ...

AstraZeneca (LSE:AZN) announced promising trial results for gefurulimab, a potential new treatment for generalized myasthenia ...

Whether it’s a cold or cancer, our body always gives us signs and warnings, but we are often too adamant or careless to listen. The brain is the master of our body; when it sneezes, the whole body ...

Detailed price information for Astrazeneca Plc Ord (AZNCF) from The Globe and Mail including charting and trades.

Astrazeneca plc seems on the way to expanding its presence in myasthenia gravis (MG) with positive “high-level” results from ...

Right to Life of Manistee County will host its annual Focus on Life dinner Aug. 11. Speaker Lisa Gigliotti will address ...

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR ...

Gefurulimab is a dual-binding nanobody designed to bind to the C5 protein in the terminal complement cascade and prevent the overactivation of the body’s immune system.

Alexion, the rare disease unit acquired by AstraZeneca nearly five years ago, has announced high-level positive results from ...